Co-delivery of docetaxel and endostatin by a biodegradable nanoparticle for the synergistic treatment of cervical cancer
- Bo Qiu†1, 3,
- Minghui Ji†2,
- Xiaosong Song3, 4,
- Yongqiang Zhu3, 4,
- Zhongyuan Wang3, 4,
- Xudong Zhang3, 4,
- Shu Wu3, 4,
- Hongbo Chen3, 4,
- Lin Mei3, 4, 5Email author and
- Yi Zheng3, 4, 5Email author
© Qiu et al; licensee Springer. 2012
Received: 11 October 2012
Accepted: 12 November 2012
Published: 6 December 2012
Cervical cancer remains a major problem in women's health worldwide. In this research, a novel biodegradable d-α-tocopheryl polyethylene glycol 1000 succinate-b-poly(ε-caprolactone-ran- glycolide) (TPGS-b-(PCL-ran-PGA)) nanoparticle (NP) was developed as a co-delivery system of docetaxel and endostatin for the synergistic treatment of cervical cancer. Docetaxel-loaded TPGS-b-(PCL-ran-PGA) NPs were prepared and further modified by polyethyleneimine for coating plasmid pShuttle2-endostatin. All NPs were characterized in size, surface charge, morphology, and in vitro release of docetaxel and pDNA. The uptake of coumarin 6-loaded TPGS-b-(PCL-ran-PGA)/PEI-pDsRED by HeLa cells was observed via fluorescent microscopy and confocal laser scanning microscopy. Endostatin expression in HeLa cells transfected by TPGS-b-(PCL-ran-PGA)/PEI-pShuttle2-endostatin NPs was detected using Western blot analysis, and the cell viability of different NP-treated HeLa cells was determined by MTT assay. The HeLa cells from the tumor model, nude mice, were treated with various NPs including docetaxel-loaded-TPGS-b-(PCL-ran-PGA)/PEI-endostatin NPs, and their survival time, tumor volume and body weight were monitored during regimen process. The tumor tissue histopathology was analyzed using hematoxylin and eosin staining, and microvessel density in tumor tissue was evaluated immunohistochemically. The results showed that the TPGS-b-(PCL-ran-PGA)/PEI NPs can efficiently and simultaneously deliver both coumarin-6 and plasmids into HeLa cells, and the expression of endostatin was verified via Western blot analysis. Compared with control groups, the TPGS-b-(PCL-ran-PGA)/PEI-pShuttle2-endostatin NPs significantly decreased the cell viability of HeLa cells (p < 0.01), inhibited the growth of tumors, and even eradicated the tumors. The underlying mechanism is attributed to synergistic anti-tumor effects by the combined use of docetaxel, endostatin, and TPGS released from NPs. The TPGS-b-(PCL-ran-PGA) NPs could function as multifunctional carrier for chemotherapeutic drugs and genetic material delivery, and offer considerable potential as an ideal candidate for in vivo cancer therapy.
KeywordsTPGS-b-(PCL-ran-PGA) nanoparticles cervical cancer endostatin docetaxel
Cervical cancer caused by high-risk human papillomavirus (HPV) persistent infection is the second most common cancer in women worldwide [1, 2]. Fortunately, two HPV vaccines (Gardasil (Merck Sharp & Dohme Corp., NJ, USA) and Cervarix (GlaxoSmithKline, TW, UK)) have been approved for use in many countries that would effectively reduce the incidence of cervical cancer genesis. However, these two vaccines have not shown any therapeutic effect against current cervical cancer, HPV infections or associated lesions . Thus, there are urgent needs to develop new specific drugs or novel therapeutic methods for cervical cancer treatment.
It has been well established that the progression of solid tumors, including cervical cancer, is critically dependent on neoangiogenesis for nutrition and oxygen supply. Therefore, blockade of neoangiogenesis has been regarded as a promising strategy for tumor therapy [4–8]. Endostatin, a 20 kDa C-terminal proteolytic fragment of collagen XVIII, has received the greatest attention for its broad-spectrum and low-toxic anti-angiogenesis ability [6, 9, 10]. These advantages accelerate the investigation process of endostatin into the clinical trial [11, 12]. However, as a protein, endostatin has many challenges in its clinical application, such as short half-life and instability. Recently, gene therapy, the use of DNA as a pharmaceutical agent, has been extensively studied in a broad range of diseases including tumors, which can achieve a relative long-term stable expression of therapeutic proteins [13–16]. A major limitation of gene therapy is the efficient delivery of therapeutic DNA to the target cells and tissues. The main vectors for DNA delivery are viral vectors and non-viral vectors having great advantages in safety, convenient large-scale production, physiological stability, and no immunogenicity.
Currently, a variety of particulate drug delivery system based on synthetic and natural materials has been investigated as DNA carriers, including liposomes , dendrimers , polycationic polymers [19, 20], and polymeric nanoparticles (NPs) . Among them, PEI-based NPs are considered as one of the most effective carrier since it can complex with pDNA or siRNA and exhibit a unique ‘proton sponge effect’ for endosomal release of the nano-complexes into cytosol . On the other hand, many chemotherapeutic drugs such as paclitaxel, doxorubicin and mitomycin are also limited because of low water solubility, acute toxicity to normal tissues due to lack of targeting, and multi-drug resistance. Several researches showed that the combination of endostatin and chemotherapeutic drugs such as docetaxel can result in better inhibitory effects for tumor growth than single therapy . However, the clinical applications of these combined drugs are needed to develop new efficient drug delivery system.
A novel biodegradable copolymer d-α-tocopheryl polyethylene glycol 1000 succinate-b-poly(ε-caprolactone-ran- glycolide) (TPGS-b-(PCL-ran-PGA)) has been successfully synthesized in our laboratory . Our previous research has confirmed that docetaxel-loaded TPGS-b-(PCL-ran-PGA) NPs can be efficiently uptaken by MCF-7 cells and effectively inhibit the growth of tumor over a longer period of time than commercial Taxotere® (Sanofi-Aventis US LLC, NJ, USA) at the same dose. To overcome the limitations of single therapy, we modified the TPGS-b-(PCL-ran-PGA) NPs with a polyplexed PEI and evaluated its ability to simultaneously deliver DNA and a chemotherapeutic drug in cells. Most importantly, we examined its therapeutic effect on xenograft models bearing cervical cancer cells.
Polymers and reagents
TPGS-b-(PCL-ran-PGA) copolymer (Mw approximately 24,000) was synthesized in our laboratory (Tsinghua University, China). Poly (vinyl alcohol) (PVA; (80% hydrolyzed), dichloromethane, branched polyethylenimine (MW approximately 25,000, BPEI25k) and 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) kit were purchased from Sigma-Aldrich Corporation (MO, USA). 4',6-diamidino-2-phenylindole (DAPI) was purchased from VECTOR (Burlingame, USA). Dulbecco's Modified Eagles' Medium (DMEM), penicillin-streptomycin, fetal bovine serum (FBS), and Dulbecco's phosphate buffered saline (DPBS) were purchased from Invitrogen-Gibco (Carlsbad, CA). Plasmid vectors pShuttle2, pIRES-EGFP, and pDsRED-E1 were acquired from Invitrogen Corporation (Clontech, USA).
Preparation of expression vectors
Human endostatin gene was amplified by PCR using the following primers: hEndostatin-F: 5′-GCTCTAGA(XbaІ)gccaccatgggaattcatgcacagccaccgcgacttcc-3′ and hEndostatin-R: 5′-GGGGTACC (KpnІ)ttacttggaggcagtcatg-3′. PCR products were digested with Xba I and KpnІ and inserted into pShuttle2 vector (Clontech). The recombinant plasmid pShuttle2-endostatin was verified by DNA sequencing. The expression of endostatin in HeLa cells transfected with PEI or TPGS-b-(PCL-ran-PGA)-based NPs was analyzed by Western blot analysis.
Preparation of docetaxel-loaded TPGS-b-(PCL-ran-PGA) NPs and determination of drug contents
Docetaxel-loaded and blank TPGS-b-(PCL-ran-PGA) NPs were prepared using a modified water-in-oil-in-water solvent evaporation as described previously . Briefly, TPGS-b-(PCL-ran-PGA) copolymer (50 mg) and a certain amount of docetaxel (0 to 25mg) were dissolved in 2 ml methylene chloride, followed by 30-s sonication to emulsify the mixture (UW 70/HD 70; tip, MS 72/D; Bandelin Electronic GmbH & Co., Berlin, Germany). After the addition of 3 ml of 7% (w/v) aqueous solution of PVA, the emulsion was sonicated again for 20 s. The resulting double emulsion was then poured into 50 ml 1% (w/v) aqueous PVA solution containing 2% isopropanol and then maintained under mechanical stirring for 1 h at 600 rpm. The residual methylene chloride was then evaporated by vacuum. Next, the 2 ml aliquots of the nanosphere suspension were washed twice with 20 mM 4-(2-hydroxyethyl)-1-piperazineethanesulfonic acid (HEPES)/NaOH (pH 7.0), and the NPs were harvested by centrifugation at 7,000 rpm for 10 min. In addition, the fluorescent coumarin-6 loaded TPGS-b-(PCL-ran-PGA) NPs were prepared in the same way except that 0.1% (w/v) coumarin-6 was entrapped instead of docetaxel.
The docetaxel-loading content, defined as the mass percentage of docetaxel entrapped in nanoparticles, was quantified using UV–vis analysis (UV-2000 UV–vis spectrophotometer, Unico Inc., WI, USA). First, docetaxel-loaded nanoparticle solutions were lyophilized to yield the solid nanoparticle samples. Then, the dried nanoparticle samples were weighed and redissolved in a mixture of chloroform and DMSO (1:1, v/v). The absorbance of docetaxel at 482.5 nm was measured, and the drug content in the solution was calculated based on a previously established calibration curve.
Preparation of PEI-modified TPGS-b-(PCL-ran-PGA) NPs/DNA complexes
The NPs were prepared as described previously . Briefly, the particles were formulated with a ratio of the polymer nitrogen to the DNA/phosphate (N/P) equal to TPGS-b-(PCL-ran-PGA) NP solution (0.2 ml) and were mixed with 2 mg of PEI in sterile HEPES-buffered saline. The PEI-modified TPGS-b-(PCL-ran-PGA) NP solution was then added to the plasmid DNA solution at different N/P ratios and vortexed gently. The PEI-modified TPGS-b-(PCL-ran-PGA) NP/DNA complexes were incubated in sterile PBS for 20 min at room temperature.
Characterization of nanoparticles
The mean particle size and size distribution were measured using dynamic light scattering (DLS) (Zetasizer Nano ZS90, Malvern Instruments Ltd., Malvern, UK). In brief, the NPs were suspended in deionized water at a concentration of 0.1 mg/ml. The mean hydrodynamic diameter was determined via cumulative analysis. The DLS determinations were predicated based on the electrophoretic mobility of the NPs in an aqueous medium. The electrophoretic mobility was evaluated using folded capillary cells in an automatic mode. Zeta potential of the NPs was detected using laser Doppler anemometry (LDA; Zetasizer Nano ZS90, Malvern Instruments Ltd.). Samples were prepared in PBS and diluted 1:3 with deionized water to ensure that the measurements were performed under conditions of low ionic strength where the surface charge of the particles can be measured accurately. The final concentration of the polymer was 0.01 mg/ml. All data represent five measurements from one sample.
Gel retardation assay
The binding of pDNA with free TPGS-b-(PCL-ran-PGA)/PEI NPs was determined by 0.8% agarose gel electrophoresis. A series of different weight ratios (w/w) of pDNA to NPs was loaded on the agarose gel (10 μl of the sample containing different amounts of pDNA). The pDNA bands were then visualized under a UV transilluminator at a wavelength of 365 nm.
Evaluation of loading efficiency of pDNA to the NPs
The loading efficiency of pDNA to the NPs was evaluated by measuring unbound pDNA in the NPs solution. The supernatant in the loaded docetaxel or free TPGS-b-(PCL-ran-PGA)/PEI NPs solution was recovered by removing the NPs by centrifugation. Free pDNA concentration in the supernatant was determined by measuring absorbance at 260 nm using a UV-2550 spectrophotometer (Shimadzu Corp., Kyoto, Japan). Loading efficiency of pDNA in NPs was determined by subtracting the amount of pDNA recovered in the washing solutions from initial amount of pDNA added. Encapsulation efficiency was defined as the percentage of pDNA encapsulated in NPs with respect to the initially added amount of pDNA.
In vitro drug release
NPs with 15 mg docetaxel-loaded TPGS-b-(PCL-ran-PGA) were dispersed in 5 ml release medium (phosphate buffer solution of pH 7.4 containing 0.1% w/v Tween 80) to form a suspension. Tween 80 was used to increase the solubility of docetaxel in the buffer solution and avoid the adherence of docetaxel to the tube wall. The suspension was transferred into a dialysis membrane bag (Spectra/Por 6, MWCO = 1,000, Spectrum Laboratories, Inc., TX, USA). Then, the closed bag was put into a centrifuge tube and immersed in 15-ml release medium. The tube was put in an orbital water bath at 37°C under a 120 rpm horizontal shaking. Ten milliliters of solution was periodically removed for analysis and was replaced with fresh release medium. The collected samples were mixed in a mixture of chloroform and DMSO (1:1, v/v). The analysis procedure was the same as described above.
To investigate the in vitro release of pDNA, 5 mg of TPGS-b-(PCL-ran-PGA)/PEI-25K (n = 6) and coumarin-6-loaded TPGS-b-(PCL-ran-PGA)/PEI (n = 6) were incubated in 1 ml of DPBS buffer (pH 7.4) in a micro-centrifuge tube in shaking incubator at 37°C. After incubating for 24 h, half of the samples (n = 3) were transferred into a 25 mM sodium acetate buffer (pH 5.0) to simulate acidication of the endolysosome of the cell. Samples were taken periodically in microcentrifuge tubes and were centrifuged at 14,000 rpm for 10 min to obtain pellet NPs. The supernatants were removed and replaced with fresh buffer, and NPs were resuspended by vigorous pipetting. The supernatants were stored at −70°C until analysis by UV measurement. Unmodified TPGS-b-(PCL-ran-PGA) NPs were also analyzed as a background control.
HeLa and 293T cells (ATCC, VA, USA) were cultured in DMEM, pH 7.4, supplemented with 25 mM NaHCO3, 10 μg/ml streptomycin sulfate, 100 μg/ml penicillin G, and 10%(v/v) FBS. Cells were maintained at 37°C in a 5% CO2, 95% air incubator.
The cytotoxicity of the NPs was determined using MTT assay. The culture medium was removed and replaced with 20 μl/well MTT (5 mg/ml) solution in each well, followed by 4-h incubation at 37°C in a fully humidified atmosphere with 5% CO2. MTT was taken up by active cells and transformed into insoluble purple formazan granules in the mitochondria. Subsequently, the medium was discarded, the precipitated formazan was dissolved in DMSO (150 μl/well), and optical density of the solution was evaluated using a microplate spectrophotometer at a wavelength of 570 nm. The analytic assays were performed every day, and at least 4 wells were randomly taken into examination each time. The determination of cell viability depends on these physical and biochemical properties of cells.
Cellular uptake of PEI-modified TPGS-b-(PCL-ran-PGA) NPs
The cells were plated in a 6-well (3 × 105 per well) plate, cultured at 37°C in 5% CO2, rinsed twice, and pre-incubated for 1 h with 2 ml of serum-free medium at 37°C. Coumarin-6-loaded TPGS-b-(PCL-ran-PGA)/PEI NPs with or without pDsRED or pIRES-EGFP were added in a particle concentration of 0.01 to 0.2 mg/ml and incubated for 1 to 4 h at 37°C. The cells were then washed three times with 1 ml of PBS (pH 7.4) to remove free PEI/plasmids-modified TPGS-b-(PCL-ran-PGA) NPs, resuspended in PBS, and then analyzed by fluorescent microscopy.
For confocal laser microscopy analysis, cells were pre-incubated for 1 h at 37°C in serum-free medium and then for 30 min to 4 h in the presence of PEI/plasmids pIRES-EGFP or/and pDsRED gene-modified TPGS-b-(PCL-ran-PGA) NPs with a final particle concentration of 0.05 mg/ml. The samples were mounted in fluorescent mounting medium (Dako, Glostrup, Denmark), and fluorescence was monitored. Images were acquired using a confocal laser microscope (Eclipse TE 2000, Nikon Corporation, Tokyo, Japan).
The cells were seeded into 6-well plates overnight, allowed to attach the bottom. Cells were cultured at 37°C in 5% CO2, rinsed twice, and pre-incubated for 1 h with 2 ml of serum-free medium at 37°C. Endostatin gene-modified TPGS-b-(PCL-ran-PGA) NPs were added in a particle concentration of 0.01 to 0.2 mg/ml and incubated for 1 to 4 h at 37°C. The cells were then washed three times with 1 ml PBS (pH 7.4) to remove any free PEI/plasmid-modified TPGS-b-(PCL-ran-PGA) NPs. After being cultured in fresh complete medium for 48 h, the cells were lysed with lysis buffer (Beyotime Institute of Biotechnology, Haimen, Jiangshu, China) containing PMSF (Sigma Chemical Co., St. Louis, MI, USA) for 30 min at 4°C. The lysate was then centrifuged for 20 min at 13,000 rpm and 4°C. The proteins were then separated through SDS-PAGE and transferred onto the PVDF membrane (Immobion-P Transfer Membrane, Millipore Corp., Billerica, MA, USA). Membranes were blocked in a tris-buffered saline with 0.1% Tween 20 solution containing 5% non-fat dry milk and incubated overnight with anti-human endostatin antibody as primary antibody at 4°C. Anti-β-actin antibody was used as loading control.
Mice maintenance and subcutaneous tumor model
Female BALB/c-nu/nu mice were supplied by the Medical Experimental Animal Center of Guangdong Province (Guangdong, China). A subcutaneous tumor model of nude mice was constructed. Six-week-old female nude mice (18 ± 2 g) were subcutaneously inoculated with 1.5 to 2 × 106 HeLa cells. When the tumor size reached about 100 mm3, the mice were randomly divided into six groups with six mice each: PBS, TPGS-b-(PCL-ran-PGA) (group ANP), TPGS-b-(PCL-ran-PGA)/PEI(group BNP), TPGS-b-(PCL-ran-PGA)/PEI-pEndostatin (group CNP), docetaxel-loaded TPGS-b-(PCL-ran-PGA) (group DNP), and docetaxel-loaded TPGS-b-(PCL-ran-PGA)/PEI-pEndostatin (group FNP), of which each dose of NPs contained 0.2 mg PCL-PGA-TPGS, 10 μg PEI, and 50 μg pDNA for treatment. The groups were treated once every 3 days with intratumoral injections of PBS or NPs. Tumor size was measured with a caliper, and the weight of each mouse was measured with a scale. Tumor volume was calculated as the equation ‘volume = length × width2 / 2’. The mean tumor volume and mouse weight were used to construct the curves of tumor growth versus mouse growth to evaluate therapeutic efficiency and toxicity.
At the end of the treatment, the mice in each group were killed and dissected. The heart, liver, lungs, spleen, kidneys, and other organs were checked for signs of toxicity. Tumor specimens were then prepared as paraffin-embedded sections for histopathological analysis. The study was carried out in strict accordance with the recommendations in the Guide for the Care and Use of Laboratory Animals of Institutional Animal Care and Use Committee of Graduate School at Shenzhen, Tsinghua University. The protocol was approved by the Animal Welfare and Ethics Committee of Graduate School at Shenzhen, Tsinghua University, China (no. 2011-YZ-BG).
Measurement of microvessel density in tumor tissues
Microvessel density (MVD) in tumor tissue was evaluated immunohistochemically using a monoclonal anti-mouse CD31 antibody (rat anti-mouse CD31 monoclonal antibody, clone MEC 13.3; BD Biosciences, NJ, USA). Tumor samples were collected after the therapy regimen was finished. Immunohistochemical staining was performed as described previously . MVD (%) was calculated from the ratio of the CD31-positive staining area to the total observation area in the viable region. Three to six fields per section were randomly analyzed, excluding necrotic areas. Positive staining areas were calculated using imaging analysis software (Win Roof; Mitani Corporation, Fukui, Japan).
Statistics and data analysis
All cell experiments were repeated at least three times unless otherwise indicated. Images of Western blot results from representative experiments were presented. The figures were created using Adobe Photoshop CS graphics program. All data were analyzed by paired t test using SPSS 11.0 software. Differences were considered statistically significant at P < 0.05.
Results and discussions
The expression of pShuttle2-endostatin
Characterization of nanoparticles
In vitro release
The cell viability of HeLa cells transfected with docetaxel-loaded NPs was decreased after 6 h, which was dose- and time-dependent. These results indicated that PEI-modified TPGS-b-(PCL-ran-PGA) NPs can simultaneously delivery docetaxel and genetic materials into cancer cells and kill them.
In vivo studies
In this research, PEI-modified docetaxel-loaded TPGS-b-(PCL-ran-PGA) NPs polyplexed with endostatin gene showed an optimizing potential in delivering genes and chemotherapeutic drugs. The co-delivery of endostatin and docetaxel by PEI-modified TPGS-b-(PCL-ran-PGA) NPs significantly inhibited the tumor growth of nude mouse models (even regress 80% established tumor). In conclusion, our study suggested that PEI-modified TPGS-b-(PCL-ran-PGA) NPs could function as an optimizing carrier for chemotherapeutic drugs and genetic materials.
BQ is an associate chief physician of the Department of Orthopedics, Renmin Hospital of Wuhan University. MJ is a Ph.D. student of the Southern Medical University. XS is a Postdoctoral Fellow, Tsinghua University. YoZ, ZW, XZ, and SW are Ph.D. students of Tsinghua University. HC and YiZ are assistant professors of the Tsinghua University. LM is an associate professor of the Tsinghua University.
The authors are grateful for the financial support from Shenzhen Bureau of Science Technology & Information (JC200903180532A, JCYJ20120614191936420, KQC201105310021A, and JC201005270308A), the Doctoral Fund of Ministry of Education of China (20090002120055), the National Natural Science Foundation of China (grant nos.: 31270019 and 81071494), the Natural Science Foundation of Guangdong Province (No. 10451805702004178 and S2012010010046), and the Program for New Century Excellent Talents in University (NCET-11-0275).
- IARC: Monographs on the evaluation of carcinogenic risks to humans: human papillomaviruses, vol. 90. http://monographs.iarc.fr/
- WHO (World Health Organization): Human papillomaviruses. http://www.who.int/vaccine_research/diseases/viral_cancers/en/index3.html
- Schiller JT, Castellsagué X, Villa LL, Hildesheim A: An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine 2008, 26(Suppl 10):K53–61.View ArticleGoogle Scholar
- Winlaw DS: Angiogenesis in the pathobiology and treatment of vascular and malignant diseases. Ann Thorac Surg 1997, 64: 1204–1211. 10.1016/S0003-4975(97)00716-9View ArticleGoogle Scholar
- Folkman J: Is angiogenesis an organizing principle in biology and medicine? J Pediatr Surg 2007, 42: 1–11. 10.1016/j.jpedsurg.2006.09.048View ArticleGoogle Scholar
- Folkman J: Antiangiogenesis in cancer therapy-endostatin and its mechanisms of action. Exp Cell Res 2006, 312: 594–607. 10.1016/j.yexcr.2005.11.015View ArticleGoogle Scholar
- Folkman J: Angiogenesis: an organizing principle for drug discovery? Nat Rev Drug Discov 2007, 6: 273–286. 10.1038/nrd2115View ArticleGoogle Scholar
- Michael SO: Antiangiogenesis and vascular endothelial growth factor/vascular endothelial growth factor receptor targeting as part of a combined-modality approach to the treatment of cancer. Int J Radiat Oncol Biol Phys 2007, 69: S64-S66.Google Scholar
- O'Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, Flynn E, Birkhead JR, Olsen BR, Folkman J: Endostatin: an endogenous inhibitor of angiogenesis and tumor growth. Cell 1997, 88: 277–285. 10.1016/S0092-8674(00)81848-6View ArticleGoogle Scholar
- Boehm T, Folkman J, Browder T, O'Reilly MS: Antiangiogenic therapy of experimental cancer does not induce acquired drug resistance. Nature 1997, 390: 404–407. 10.1038/37126View ArticleGoogle Scholar
- Herbst RS, Lee AT, Tran HT, Abbruzzese JL: Clinical studies of angiogenesis inhibitors: the University of Texas MD Anderson Center Trial of Human Endostatin. Curr Oncol Rep 2001, 3: 131–140. 10.1007/s11912-001-0013-8View ArticleGoogle Scholar
- Zhuang HQ, Yuan ZY: Process in the mechanisms of endostatin combined with radiotherapy. Cancer Letters 2009, 282: 9–13. 10.1016/j.canlet.2008.12.008View ArticleGoogle Scholar
- Alexander BL, Ali RR, Alton EW, Bainbridge JW, Braun S, Cheng SH, Flotte TR, Gaspar HB, Grez M, Griesenbach U, Kaplitt MG, Ott MG, Seger R, Simons M, Thrasher AJ, Thrasher AZ, Ylä-Herttuala S: Progress and prospects: gene therapy clinical trials (part 1). Gene Ther 2007, 20: 1439–1447.Google Scholar
- Guinn BA, Mulherkar R: International progress in cancer gene therapy. Cancer Gene Ther 2008, 12: 765–775.View ArticleGoogle Scholar
- Scherer L, Rossi JJ, Weinberg MS: Progress and prospects: RNA-based therapies for treatment of HIV infection. Gene Ther 2007, 14: 1057–1064. 10.1038/sj.gt.3302977View ArticleGoogle Scholar
- Androic I, Krämer A, Yan R, Rödel F, Gätje R, Kaufmann M, Strebhardt K, Yuan J: Targeting cyclin B1 inhibits proliferation and sensitizes breast cancer cells to taxol. BMC Cancer 2008, 8: 391–401. 10.1186/1471-2407-8-391View ArticleGoogle Scholar
- Gao Y, Liu XL: Research progress on siRNA delivery with nonviral carriers. Int J Nanomedicine 2011, 6: 1017–1025.View ArticleGoogle Scholar
- Zhou J, Wu J, Hafdi N: PAMAM dendrimers for efficient siRNA delivery and potent gene silencing. Chem Commun (Camb) 2006, 22: 2362–2364.View ArticleGoogle Scholar
- Mao SR, Sun W, Kissel T: Chitosan-based formulations for delivery of DNA and siRNA. Adv Drug Deliv Rev 2010, 62: 12–27. 10.1016/j.addr.2009.08.004View ArticleGoogle Scholar
- Son S, Kim WJ: Biodegradable nanoparticles modified by branched polyethylenimine for plasmid DNA delivery. Biomaterials 2010, 31: 133–143. 10.1016/j.biomaterials.2009.09.024View ArticleGoogle Scholar
- Blum JS, Saltzman WM: High loading efficiency and tunable release of plasmid DNA encapsulated in submicron particles fabricated from PLGA conjugated with poly-l-lysine. J Control Release 2008, 129: 66–72. 10.1016/j.jconrel.2008.04.002View ArticleGoogle Scholar
- Boussif O, Lezoualc'h F, Zanta MA, Mergny MD, Scherman D, Demeneix B, Behr JP: A versatile vector for gene and oligonucleotide transfer into cells in culture and in vivo: polyethylenimine. Proc Natl Acad Sci USA 1995, 92: 7297–7301. 10.1073/pnas.92.16.7297View ArticleGoogle Scholar
- Zhu LP, Xing J, Wang QX, Kou L, Li C, Hu B, Wu ZW, Wang JJ, Xu GX: Therapeutic efficacy of recombinant human endostatin combined with chemotherapeutics in mice-transplanted tumors. Eur J Pharmacol 2009, 617: 23–27. 10.1016/j.ejphar.2009.07.003View ArticleGoogle Scholar
- Huang L, Chen H, Zheng Y, Song X, Liu R, Liu K, Zeng X, Mei L: Nanoformulation of d-α-tocopheryl polyethylene glycol 1000 succinate-b-poly(ε-caprolactone-ran-glycolide) diblock copolymer for breast cancer therapy. Integr Biol 2011, 3: 993–1002. 10.1039/c1ib00026hView ArticleGoogle Scholar
- Kim JH, Park JS, Yang HN, Woo DG, Jeon SY, Do HJ, Lim HY, Kim JM, Park KH: The use of biodegradable PLGA nanoparticles to mediate SOX9 gene delivery in human mesenchymal stem cells (hMSCs) and induce chondrogenesis. Biomaterials 2011, 32: 268–278. 10.1016/j.biomaterials.2010.08.086View ArticleGoogle Scholar
- Wang C, Ge Q, Ting D, Nguyen D, Shen HR, Chen J, Eisen HN, Heller J, Langer R, Putnam D: Molecularly engineered poly (ortho ester) microspheres for enhanced delivery of DNA vaccines. Nat Mater 2004, 3: 190–196. 10.1038/nmat1075View ArticleGoogle Scholar
- Zolnik BS, Burgess DJ: Effect of acidic pH on PLGA microsphere degradation and release. J Control Release 2007, 122: 338–344. 10.1016/j.jconrel.2007.05.034View ArticleGoogle Scholar
- Yin Y, Chen D, Qiao M, Wei X, Hu H: Lectin-conjugated PLGA nanoparticles loaded with thymopentin: ex vivo bioadhesion and in vivo biodistribution. J Control Release 2007, 123: 27–38. 10.1016/j.jconrel.2007.06.024View ArticleGoogle Scholar
- Kataoka K, Matsumoto T, Yokoyama M, Okano T, Sakurai Y, Fukushima S, Okamoto K, Kwon GS: Doxorubicin-loaded poly(ethylene glycol)-poly(beta-benzyl-L-aspartate) copolymer micelles: their pharmaceutical characteristics and biological significance. J Control Release 2000, 64: 143–153. 10.1016/S0168-3659(99)00133-9View ArticleGoogle Scholar
- Lee AL, Wang Y, Cheng HY, Pervaiz S, Yang YY: The co-delivery of paclitaxel and Herceptin using cationic micellar nanoparticles. Biomaterials 2009, 30: 919–927. 10.1016/j.biomaterials.2008.10.062View ArticleGoogle Scholar
- Fay F, Quinn DJ, Gilmore BF, McCarron PA, Scott CJ: Gene delivery using dimethyldidodecylammonium bromide-coated PLGA nanoparticles. Biomaterials 2011, 31: 4214–4222.View ArticleGoogle Scholar
- Wang L, Yao B, Li Q, Mei K, Xu JR, Li HX, Wang YS, Wen YJ, Wang XD, Yang HS, Li YH, Luo F, Wu Y, Liu YY, Yang L: Gene therapy with recombinant adenovirus encoding endostatin encapsulated in cationic liposome in coxsackievirus and adenovirus receptor-deficient colon carcinoma murine models. Hum Gene Ther 2011, 22(9):1061–1069. 10.1089/hum.2011.014View ArticleGoogle Scholar
- Collnot EM, Baldes C, Wempe MF, Kappl R, Hüttermann J, Hyatt JA, Edgar KJ, Schaefer UF, Lehr CM: Mechanism of inhibition of P-glycoprotein mediated efflux by vitamin E TPGS: influence on ATPase activity and membrane fluidity. Mol Pharm 2007, 4(3):465–474. 10.1021/mp060121rView ArticleGoogle Scholar
- Dintaman JM, Silverman JA: Inhibition of P-glycoprotein by Dalpha-tocopheryl polyethylene glycol 1000 succinate (TPGS). Pharm Res 1999, 16: 1550–1556. 10.1023/A:1015000503629View ArticleGoogle Scholar
This article is published under license to BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.